BACKGROUND: Fabry disease is a treatable X-linked lysosomal storage disorder caused by alterations in the structural gene (GLA) of α-galactosidase A (AGAL), manifesting with cardiovascular and/or kidney disease and decreased life span. Although males as well as females can be affected, females cannot be identified using AGAL activity. We evaluated urinary total globotriaosylceramide (Gb3) and single N-acyl isoforms for the detection of Fabry disease in female patients with and without chronic kidney disease (CKD). STUDY DESIGN: Diagnostic accuracy study. SETTING & PARTICIPANTS: 28 untreated women with Fabry disease and 335 female outpatients without Fabry disease with (n = 213) and without CKD (n = 122). INDEX TEST: Assessment of urinary Gb3 using electrospray ionization tandem mass spectrometry, including 6 N-acyl isoforms, total Gb3 related to urinary creatinine, and ratios of Gb3-24 to Gb3-18 and Gb3-24 to urinary AGAL. REFERENCE TEST: Fabry disease, diagnosed by identification of known pathogenic GLA mutations in patients or their male relatives. RESULTS: 6 parameters (ratio of Gb3-24 to urinary AGAL activity; Gb3-24; ratio of Gb3-24 to Gb3-18; Gb3-22; Gb3-16; and total Gb3) were highly informative for the diagnosis of Fabry disease independent of the presence or absence of CKD (area under the receiver operating characteristic curve, 0.876-0.927; all P < 0.001). LIMITATIONS: Because of low signal-to-noise ratios, 15.8% of samples had to be excluded. CONCLUSION: Total urinary Gb3 and Gb3 isoforms can be used for the diagnosis of Fabry disease in women.
RCT Entities:
BACKGROUND:Fabry disease is a treatable X-linked lysosomal storage disorder caused by alterations in the structural gene (GLA) of α-galactosidase A (AGAL), manifesting with cardiovascular and/or kidney disease and decreased life span. Although males as well as females can be affected, females cannot be identified using AGAL activity. We evaluated urinary total globotriaosylceramide (Gb3) and single N-acyl isoforms for the detection of Fabry disease in female patients with and without chronic kidney disease (CKD). STUDY DESIGN: Diagnostic accuracy study. SETTING & PARTICIPANTS: 28 untreated women with Fabry disease and 335 female outpatients without Fabry disease with (n = 213) and without CKD (n = 122). INDEX TEST: Assessment of urinary Gb3 using electrospray ionization tandem mass spectrometry, including 6 N-acyl isoforms, total Gb3 related to urinary creatinine, and ratios of Gb3-24 to Gb3-18 and Gb3-24 to urinary AGAL. REFERENCE TEST: Fabry disease, diagnosed by identification of known pathogenic GLA mutations in patients or their male relatives. RESULTS: 6 parameters (ratio of Gb3-24 to urinary AGAL activity; Gb3-24; ratio of Gb3-24 to Gb3-18; Gb3-22; Gb3-16; and total Gb3) were highly informative for the diagnosis of Fabry disease independent of the presence or absence of CKD (area under the receiver operating characteristic curve, 0.876-0.927; all P < 0.001). LIMITATIONS: Because of low signal-to-noise ratios, 15.8% of samples had to be excluded. CONCLUSION: Total urinary Gb3 and Gb3 isoforms can be used for the diagnosis of Fabry disease in women.
Authors: Britt Johnson; Hermann Mascher; Daniel Mascher; Elisa Legnini; Christina Y Hung; Angela Dajnoki; Yin-Hsiu Chien; László Maródi; Wuh-Liang Hwu; Olaf A Bodamer Journal: Ann Lab Med Date: 2013-06-24 Impact factor: 3.464
Authors: Andreas D Kistler; Justyna Siwy; Frank Breunig; Praveen Jeevaratnam; Alexander Scherl; William Mullen; David G Warnock; Christoph Wanner; Derralynn A Hughes; Harald Mischak; Rudolf P Wüthrich; Andreas L Serra Journal: PLoS One Date: 2011-06-15 Impact factor: 3.240
Authors: Jan Lukas; Joan Torras; Itziar Navarro; Anne-Katrin Giese; Tobias Böttcher; Hermann Mascher; Karl J Lackner; Guenter Fauler; Eduard Paschke; Josep M Cruzado; Ales Dudesek; Matthias Wittstock; Wolfgang Meyer; Arndt Rolfs Journal: Clin Kidney J Date: 2012-10
Authors: Mustafa A Kamani; Philippe Provençal; Michel Boutin; Natalia Pacienza; Xin Fan; Anton Novak; Tonny C Huang; Beth Binnington; Bryan C Au; Christiane Auray-Blais; Clifford A Lingwood; Jeffrey A Medin Journal: Future Sci OA Date: 2016-10-13
Authors: Martina Gaggl; Natalija Lajic; Georg Heinze; Till Voigtländer; Raute Sunder-Plassmann; Eduard Paschke; Günter Fauler; Gere Sunder-Plassmann; Gerald Mundigler Journal: Int J Med Sci Date: 2016-04-26 Impact factor: 3.738